Condyloma acuminata
Adult: 1 million IU into each lesion (Max 5 lesions per treatment course) 3 times weekly (every other day) for 3 weeks; repeat after 12-16 weeks as needed. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Parenteral
AIDS-related Kaposi's sarcoma
Adult: 30 million IU/m2 3 times weekly via SC or IM inj. Continue until disease progression or until a maximal response has been achieved after 16 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Parenteral
Malignant melanoma
Adult: As adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence (e.g. patients with primary or recurrent [clinical or pathological] lymph node involvement): Induction: 20 million IU/m2 via IV infusion over 20 minutes for 5 consecutive days a week for 4 weeks. Maintenance: 10 million IU//m2 via SC inj 3 times weekly (every other day) for 48 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Parenteral
Hairy cell leukaemia
Adult: 2 million IU/m2 via SC or IM inj 3 times weekly (every other day) for up to 6 months. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Parenteral
Chronic hepatitis B
Adult: In cases wherein, there is evidence of hepatitis B viral replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBAg), elevated ALT and histologically proven active liver inflammation and/or fibrosis: 5-10 million IU via SC inj 3 times weekly (every other day) for 4-6 months. Alternatively, 30-35 million IU weekly (either as 5 million IU daily or as 10 million IU 3 times weekly) via SC or IM inj for 16 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Child: ≥1 year 3 million IU/m2 via SC inj 3 times weekly for the 1st week then increased to 6 million IU/m2 3 times weekly (Max 10 million IU 3 times weekly) administered subcutaneously for a total duration of 16-24 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Child: ≥1 year 3 million IU/m2 via SC inj 3 times weekly for the 1st week then increased to 6 million IU/m2 3 times weekly (Max 10 million IU 3 times weekly) administered subcutaneously for a total duration of 16-24 weeks. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Parenteral
Chronic hepatitis C
Adult: In patients with compensated liver disease and who are positive for hepatitis C virus RNA (HCV-RNA): 3 million IU via SC or IM inj 3 times weekly (every other day) for 6-12 months (depending on genotype and patient’s response) when used with ribavirin, or for 6-18 months when used as monotherapy. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Child: ≥3 years In patients with compensated liver disease, not previously treated, and who are positive for HCV-RNA, in combination with ribavirin: 3 million IU/m2 via SC inj 3 times weekly (every other day) for 1 year (genotype 1) or for 24 weeks (genotype 2/3). Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Child: ≥3 years In patients with compensated liver disease, not previously treated, and who are positive for HCV-RNA, in combination with ribavirin: 3 million IU/m2 via SC inj 3 times weekly (every other day) for 1 year (genotype 1) or for 24 weeks (genotype 2/3). Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Carcinoid tumours
Adult: Treatment of carcinoid tumours with lymph node or liver metastases and with carcinoid syndrome: 5 million IU (3-9 million IU) 3 times weekly (every other day). Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Follicular lymphoma
Adult: As adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen: 5 million IU 3 times weekly (every other day) for up to 18 months. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Chronic myeloid leukaemia
Adult: 4-5 million IU/m2 daily. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Multiple myeloma
Adult: As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy: 3 million IU/m2 3 times weekly (every other day). Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Indications and routes of administration may vary among countries or individual products. Refer to specific product guidelines.